16 Matching Annotations
  1. Last 7 days
  2. aacrjournals.org aacrjournals.org
    Tislelizumab and hypofractionated radiotherapy plus nab-paclitaxel/gemcitabine as conversion therapy for BRPC/LAPC: A Phase II trial with dynamic biomarker monitoring
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    aacrjournals.org/clincancerres/article/32/3/516/772021/Tislelizumab-and-Hypofractionated-Radiotherapy
  3. aacrjournals.org aacrjournals.org
    Redefining Treatment Paradigms for Glioma in Adolescents and Young Adults: Population-Based Evidence for Molecular Classification
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    aacrjournals.org/clincancerres/article/32/7/1349/775522/Redefining-Treatment-Paradigms-for-Glioma-in
  4. Mar 2026
  5. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    Metastatic progression of pheochromocytoma and paraganglioma occurs via parallel evolution
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC12963421/
  6. May 2025
  7. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    The genomic landscape of benign and malignant thyroid tumors from individuals carrying germline PTEN variants is distinct from sporadic thyroid cancers
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC11534558/
  8. Apr 2025
  9. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC11962403/
  10. Jan 2025
  11. link.springer.com link.springer.com
    Sex disparities in the association between rare earth elements exposure and genetic mutation frequencies in lung cancer patients
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    link.springer.com/article/10.1038/s41598-024-79580-z
  12. Oct 2024
  13. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    Biomarker analyses investigating disease biology and associations with outcomes in the JAVELIN Merkel 200 trial of avelumab in metastatic Merkel cell carcinoma
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC11443199/
  14. Feb 2024
  15. 52.53.155.43 52.53.155.43
    can-23-1129-html.html
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    52.53.155.43/f18faff86a38ad159824c95dcf032e1a8bb0e968/133-html.html
  16. Jan 2024
  17. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    Leveraging tissue-specific enhancer-target gene regulatory networks identifies enhancer somatic mutations that functionally impact lung cancer
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC10758689/
  18. Dec 2023
  19. 52.53.155.43 52.53.155.43
    can-23-1129-html.html
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    52.53.155.43/f18faff86a38ad159824c95dcf032e1a8bb0e968/133-html.html
  20. Nov 2023
  21. www.sciencedirect.com www.sciencedirect.com
    Unveiling the metal mutation nexus: Exploring the genomic impacts of heavy metal exposure in lung adenocarcinoma and colorectal cancer
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S0304389423018733
  22. Oct 2023
  23. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    Neoantigen targetability in progressive advanced melanoma
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC10570682/
  24. 52.53.155.43 52.53.155.43
    ccr-23-1106-html.html
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    52.53.155.43/e699d5a890495f1b3d64be1323ae2437b422136a/ccr-23-1106-html.html
  25. Sep 2023
  26. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    Identifying mechanisms of resistance by circulating tumour DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at time of PARP Inhibitor Progression
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC10502468/
  27. Aug 2023
  28. 52.53.155.43 52.53.155.43
    ccr-23-1106-html.html
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    52.53.155.43/e699d5a890495f1b3d64be1323ae2437b422136a/ccr-23-1106-html.html
  29. Jul 2023
  30. 52.53.155.43 52.53.155.43
    ccr-23-0797-html.html
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    52.53.155.43/2c803156d89f9529c07ad3c21352a7e38912e0ae/ccr-23-0797-html.html